Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

This study has been completed.
Information provided by (Responsible Party):
Victor Montori, Mayo Clinic Identifier:
First received: December 20, 2007
Last updated: February 1, 2016
Last verified: February 2016
To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to bisphosphonates.

Condition Intervention
Bone Loss, Age Related
Postmenopausal Bone Loss
Postmenopausal Osteoporosis
Behavioral: Osteoporosis Choice Decision Aid

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single Blind (Participant)
Official Title: Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Evidence of success of decision aid to providers and patients, which leads to improved knowledge, reduced decisional conflict and enhanced satisfaction with the decision, and enhanced adherence to medication. [ Time Frame: Directly following intervention. ]

Secondary Outcome Measures:
  • Evaluate ability to recruit participants and collect patient outcomes. [ Time Frame: One year after start of study. ]

Enrollment: 100
Study Start Date: August 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Behavioral: Osteoporosis Choice Decision Aid
The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
No Intervention: Arm 2

Detailed Description:
Bisphosphonates can reduce fracture risk in patients with osteoporosis. However, many patients may not start and adhere to bisphosphonates, consequently losing independence, quality, and length of life. We hypothesize that a decision aid that efficiently improves patient education and communication with their provider about fracture risk, and about using bisphosphonates to reduce that risk, will improve the quality of treatment decisions. We anticipate that patients will become more involved in the decision-making process and decisions will be more consistent with patients' values and health care goals. We expect this will lead to increased bisphosphonate start and adherence and improved patient outcomes.

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female, post-menopausal women aged 50 to 90.
  • Have a bone mineral density (BMD) evaluation resulting in a T-Score of <-1.0.
  • Have a follow-up appointment with a provider in the areas of Family Medicine (FM), Primary Care Internal Medicine (PCIM), or POM.
  • Have no major barriers (i.e., severe hearing impairment, dementia, require interpreter, etc.) to participation in shared decision-making (per provider's assessment)
  • Enrollment is open to females of diverse racial backgrounds.

Exclusion Criteria:

  • Currently taking a bisphosphonate.
  • Not available for 6 month follow-up phone call.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00578981

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Victor M. Montori, M.D. Mayo Clinic
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Victor Montori, MD, Mayo Clinic Identifier: NCT00578981     History of Changes
Other Study ID Numbers: 07-003475
Study First Received: December 20, 2007
Last Updated: February 1, 2016

Keywords provided by Mayo Clinic:
Osteoporosis, age-related
Osteoporosis, Postmenopausal
Bone Loss
Low Bone Density

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on April 25, 2017